Market Overview

Sarah Cannon Research Institute Names New Executive to Leadership Team

NASHVILLE, Tenn.--(BUSINESS WIRE)--

Sarah Cannon Research Institute (SCRI) has named Cindy Perettie president, SCRI Services. In this role, Perettie will provide executive oversight of its Services/CRO line of business, which specializes in innovative clinical research services with a unique focus on early phase oncology drug development programs.

“Cindy brings over two decades of global drug development experience in clinical development and operations from the pharmaceutical and healthcare industry,” SCRI Chief Executive Officer Dee Anna Smith said. “Her executive leadership will help us continue to enhance our service offering and further our mission of advancing therapies for patients.”

Perettie previously served as vice president of regulatory documentation and operations at Roche/Genentech, where she was responsible for the global filing strategies, document development and submission to global health authorities. Prior to that role, she held the position of life cycle leader for Avastin, where she was accountable globally for numerous development and commercial programs. She also served as Genentech's regional head of international development for Europe, the Middle East and Africa, overseeing drug development in those regions with an organization comprising clinical and regulatory functions.

“This critical appointment strengthens our Services division and deepens the breadth of our leadership," said SCRI Chief Medical Officer Howard A. Burris III, M.D. “Cindy has a proven track record for using her global health industry knowledge to create value and a competitive advantage.”

Perettie holds a B.S. in biochemistry from State University of New York and an M.B.A. from St. Mary's College. She is currently a member of, or performs a role for, numerous groups such as the American Association for the Advancement of Science, Drug Information Association, and Healthcare Business Association. Additionally, she serves as chairman of the BIO Pharmacovigilance Group.

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com.

Sarah Cannon Research Institute (SCRI)
Anna Walker, 615-329-7216
anna.walker@scresearch.net

 

Around the Web, We're Loving...

Get Benzinga's Newsletters